KRSA
Cyclerion Therapeutics, Inc.
There isn't enough reported data to score KRSA yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
KRSA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
KRSA's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
KRSA PE Valuation
KRSA has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
KRSA Forward outlook
There aren't enough analyst estimates for KRSA to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
KRSA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$12.36 | -$7.18 |
| Q2 2026 | -$11.27 | -$6.16 |
| Q1 2026 | -$9.17 | -$1.12 |
| Q4 2025 | -$7.77 | +$0.70 |
| Q3 2025 | -$5.18 | +$9.16 |
| Q2 2025 | -$5.11 | -176% |
| Q1 2025 | -$8.05 | -$5.68 |
| Q4 2024 | -$8.47 | +$11.96 |
KRSA lost $12.36 per share over the past year, and its loss has widened in each of the last five quarters.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over KRSA on earnings quality, reporting a profit while its opponent remains loss making.
KRSA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $1M | -43% |
| Q3 2025 | $875K | +351% |
| Q4 2022 | $608K | +14% |
| Q2 2022 | $306K | -90% |
| Q1 2022 | $711K | +1047% |
| Q4 2021 | $533K | +301% |
| Q3 2021 | $348K | -13% |
| Q2 2021 | $3M | +301% |
KRSA's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -82% | -110 points |
| Q3 2025 | -115% | +467 points |
| Q2 2025 | -1798% | N/A |
| Q1 2025 | -1799% | N/A |
| Q4 2024 | 28% | N/A |
| Q3 2024 | -581% | N/A |
| Q4 2022 | -1209% | +1482 points |
| Q2 2022 | -4390% | -3851 points |
KRSA's operating margin was −82% last quarter, down 110 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over KRSA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
KRSA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$47.1M | -$46.8M |
| Q2 2026 | -$1.4M | -$929K |
| Q1 2026 | -$1.2M | -$274K |
| Q4 2025 | -$1.6M | -539% |
| Q3 2025 | -$264K | +$1.5M |
| Q2 2025 | -$503K | +$603K |
| Q1 2025 | -$968K | +$903K |
| Q4 2024 | $360K | +$1.9M |
KRSA has burned cash in almost every quarter: −$51M over the past year, against −$1M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over KRSA on cash generation, producing positive trailing cash flow while its opponent burns cash.
KRSA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2127% | +12.9M shares |
| 1 year | +2983% | +13.1M shares |
| 3 years | +4049% | +13.2M shares |
| 5 years | +5456% | +13.3M shares |
KRSA has 14M diluted shares, up 2983% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over KRSA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
KRSA Net Leverage
KRSA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
KRSA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.4 | Neutral |
| Stochastic | 63.2 | Neutral |
KRSA's weekly RSI is 58 (neutral) and its Stochastic is 63 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
KRSA PE vs Healthcare Sector
| Metric | KRSA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
KRSA has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
KRSA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.5 | 0.5% below |
| 20 week MA | $28.9 | 8.2% above |
| 50 week MA | $21.1 | 48% above |
| 100 week MA | $20.1 | 55% above |
| 200 week MA | $25.3 | 24% above |
KRSA has slipped below its 8-week average, but it's still above the other four, and 24% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
KRSA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $355.6 | $436.8 | +23% |
| 2021 | $436.8 | $245.0 | -44% |
| 2022 | $245.0 | $76.4 | -69% |
| 2023 | $76.4 | $23.5 | -69% |
| 2024 | $23.5 | $23.1 | -1.5% |
| 2025 | $23.1 | $9.45 | -59% |
| 2026 YTD | $9.45 | $31.3 | +231% |
KRSA has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.